Home » Stocks » Bristol-Myers Squibb

Bristol-Myers Squibb Company (BMY)

Stock Price: $61.53 USD 0.20 (0.33%)
Updated Aug 7, 2020 9:31 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 139.22B
Revenue (ttm) 31.01B
Net Income (ttm) -563.00M
Shares Out 2.26B
EPS (ttm) 0.51
PE Ratio 120.65
Forward PE 9.62
Dividend $1.80
Dividend Yield 2.93%

Stock Quote

Trading Day Aug 7, 2020
Last Price $61.53
Previous Close $61.33
Change ($) 0.20
Change (%) 0.33%
Day's Open 62.00
Day's Range 61.48 - 61.59
Day's Volume 218,350
52-Week Range 45.08 - 68.34

More Stats

Market Cap 139.22B
Enterprise Value 164.24B
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date Jul 2, 2020
Shares Outstanding 2.26B
Float 2.26B
EPS (basic) -0.28
EPS (diluted) 0.51
FCF / Share 5.30
Dividend $1.80
Dividend Yield 2.93%
Earnings Yield 0.83%
FCF Yield 8.62%
Payout Ratio n/a
Shares Short 22.89M
Short Ratio 1.49
Short % of Float 1.01%
Beta 0.70
PE Ratio 120.65
Forward PE 9.62
P/FCF Ratio 11.60
PS Ratio 4.49
PB Ratio 2.68
Revenue 31.01B
Operating Income 2.54B
Net Income -563.00M
Free Cash Flow 12.00B
Net Cash -25.01B
Net Cash / Share -11.05
Gross Margin 61.04%
Operating Margin 8.20%
Profit Margin -1.60%
FCF Margin 38.70%
ROA 5.82%
ROE 3.00%
ROIC 5.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (17)

Buy 9
Overweight 3
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$71.67*
(16.48% upside)
Low
62.0
Current: $61.53
High
81.0
Target: 71.67
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue26,14522,56120,77619,42716,56015,87916,38517,62121,24419,484
Revenue Growth15.89%8.59%6.94%17.31%4.29%-3.09%-7.01%-17.05%9.03%-
Gross Profit18,06716,09414,76214,45812,65111,94711,76613,01115,64614,207
Operating Income4,9755,9685,1315,9152,0772,3812,8912,3406,9816,071
Net Income3,4394,9201,0074,4571,5652,0042,5631,9603,7093,102
Shares Outstanding1,6291,6321,6371,6711,6681,6591,6471,6511,6951,712
Earnings Per Share2.013.010.612.650.931.201.541.162.161.79
EPS Growth-33.22%393.44%-76.98%184.95%-22.5%-22.08%32.76%-46.3%20.67%-
Dividend Per Share1.641.601.561.141.491.451.761.361.320.96
Dividend Growth2.5%2.56%36.84%-23.49%2.76%-17.61%29.41%3.03%37.5%-
Operating Cash Flow8,0675,9405,2753,0582,1053,1483,5456,9414,8404,491
Capital Expenditures-836-951-1,055-1,215-820-526-537-548-367-424
Free Cash Flow7,2314,9894,2201,8431,2852,6223,0086,3934,4734,067
Cash & Equivalents15,3938,7596,8126,3504,2707,4354,5252,8298,7337,301
Total Debt46,7337,3497,9626,7086,6897,8328,3407,3945,4915,445
Net Cash / Debt-31,3401,410-1,150-358-2,419-397-3,815-4,5653,2421,856
Assets129,94434,98633,55133,70731,74833,74938,59235,89732,97031,076
Liabilities78,24620,85921,70417,36017,32418,76623,35622,25917,10315,438
Book Value51,59814,03111,74116,17714,26614,85215,15413,62315,95615,713
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bristol-Myers Squibb Company
Country United States
Employees 30,000
CEO Giovanni Caforio

Stock Information

Ticker Symbol BMY
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: BMY

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in the following therapeutic classes: hematology, oncology, cardiovascular, and immunology. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, and Ubiquigent Limited; clinical collaboration agreement with NeoImmuneTech, Inc.; and partnership with Astrazeneca Plc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.